Theragenics Corp

TGX-N

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about TGX-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
December 6, 2011
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
December 6, 2011
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
PAST TOP PICK
PAST TOP PICK
November 3, 2011
(A Top Pick Nov 11/10. Up 28.57%.)
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
November 3, 2011
(A Top Pick Nov 11/10. Up 28.57%.)
PAST TOP PICK
PAST TOP PICK
October 4, 2011
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
October 4, 2011
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
TOP PICK
TOP PICK
November 11, 2010
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
November 11, 2010
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
TOP PICK
TOP PICK
December 24, 2007
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
December 24, 2007
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
WEAK BUY
WEAK BUY
October 6, 2006
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
October 6, 2006
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
PAST TOP PICK
PAST TOP PICK
January 30, 2006
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
January 30, 2006
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
TOP PICK
TOP PICK
September 6, 2005
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
September 6, 2005
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
TOP PICK
TOP PICK
January 12, 2005
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
January 12, 2005
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
PAST TOP PICK
PAST TOP PICK
November 9, 2004
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
November 9, 2004
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
TOP PICK
TOP PICK
September 16, 2004
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
Show full opinionHide full opinion
Theragenics Corp (TGX-N)
September 16, 2004
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
TOP PICK
TOP PICK
July 16, 2004
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
Show full opinionHide full opinion
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »